Lilly Calls It Quits On Pegilodecakin As Loxo Team Reorganizes Cancer R&D

 
• By Joseph Haas
  
Pruning of ornamental trees by scissors
Lilly said it has no plans for further trials of pegilodecakin and terminated three earlier-stage cancer candidates
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business